New developments in treating glycosphingolipid storage diseases.

New developments in treating glycosphingolipid storage diseases.

Bibliografski detalji
Glavni autori:	Platt, F, Jeyakumar, M, Andersson, U, Dwek, R, Butters, T
Format:	Journal article
Jezik:	English
Izdano:	2005

Slični predmeti

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
od: Jeyakumar, M, i dr.
Izdano: (2002)

New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
od: Butters, T, i dr.
Izdano: (2003)

Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders.
od: Butters, T, i dr.
Izdano: (2000)

Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
od: Platt, F, i dr.
Izdano: (2000)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
od: Andersson, U, i dr.
Izdano: (2000)

Lysosomal storage of oligosaccharide and glycosphingolipid in imino sugar treated cells.
od: Boomkamp, S, i dr.
Izdano: (2010)

Storage solutions: treating lysosomal disorders of the brain.
od: Jeyakumar, M, i dr.
Izdano: (2005)

Pharmacological impairment of acrosome formation and sperm head morphogenesis reveals essential role of glycosphingolipids in spermiogenesis
od: van der Spoel, A, i dr.
Izdano: (2002)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
od: Priestman, D, i dr.
Izdano: (2008)

Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases
od: Silk, J, i dr.
Izdano: (2005)

Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases.
od: Gadola, S, i dr.
Izdano: (2006)

Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis.
od: Mellor, H, i dr.
Izdano: (2004)

Modulation of THP-1 macrophage and cholesterol-loaded foam cell apolipoprotein E levels by glycosphingolipids.
od: Garner, B, i dr.
Izdano: (2002)

Substrate reduction therapy for glycosphingolipid storage disorders.
od: Lachmann, R, i dr.
Izdano: (2001)

Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis
od: Butters, T, i dr.
Izdano: (2000)

ALTERED AUTOPHAGY AND APP METABOLISM IN GLYCOSPHINGOLIPID STORAGE DISEASES
od: Boland, B, i dr.
Izdano: (2011)

Glycosphingolipid disorders of the brain.
od: Boomkamp, S, i dr.
Izdano: (2008)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
od: Platt, F, i dr.
Izdano: (2003)

Introduction: Glycosphingolipids in cell biology and disease.
od: Sillence, D, i dr.
Izdano: (2004)

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
od: Andersson, U, i dr.
Izdano: (2004)

Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling.
od: Neville, D, i dr.
Izdano: (2004)

Therapeutic applications of imino sugars in lysosomal storage disorders.
od: Butters, T, i dr.
Izdano: (2003)

Iminosugar inhibitors for treating the lysosomal glycosphingolipidoses
od: Butters, T, i dr.
Izdano: (2005)

Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport.
od: te Vruchte, D, i dr.
Izdano: (2004)

Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
od: Butters, T, i dr.
Izdano: (2005)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
od: te Vruchte, D, i dr.
Izdano: (2010)

Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice.
od: Garner, B, i dr.
Izdano: (2002)

Glycosphingolipids in endocytic membrane transport.
od: Sillence, D, i dr.
Izdano: (2004)

Diverse endogenous antigens for mouse NKT cells: self-antigens that are not glycosphingolipids.
od: Pei, B, i dr.
Izdano: (2011)

The apo E gene knockout mouse as a model to study the potential atherogenic properties of glycosphingolipids
od: Garner, B, i dr.
Izdano: (2003)

Apoptotic modification of glycosphingolipids of human granulocytes
od: A. M. Tomin, i dr.
Izdano: (2012-09-01)

The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases
od: James A. Shayman, i dr.
Izdano: (2014-07-01)

Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice
od: Brett Garner, i dr.
Izdano: (2002-02-01)

Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease
od: Wallom, K-L, i dr.
Izdano: (2021)

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
od: Platt, F, i dr.
Izdano: (2001)

Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
od: Andersson, U, i dr.
Izdano: (2004)

Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.
od: Butters, T, i dr.
Izdano: (2003)

Activation state and intracellular trafficking contribute to the repertoire of endogenous glycosphingolipids presented by CD1d [corrected].
od: Muindi, K, i dr.
Izdano: (2010)

Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease
od: Ersek, A, i dr.
Izdano: (2015)

Iminosugars and methods of treating viral diseases
od: Ramstedt, U, i dr.
Izdano: (2011)